According to recent foreign media reports, global medical device giant Medtronic announced that it will acquire Scientia Vascular for $550 million to strengthen its stroke treatment portfolio.

Image source: Fierce Biotech

Scientia Vascular is a company specializing in the manufacture of specialized guidewires, microcatheters, and access products for reaching complex blood clots deep in the brain. According to data from PharmNet Medical Devices, the company has already launched 16 products in the United States.

In 2021, Scientia completed a $50 million funding round, which the company reportedly used to accelerate sales, marketing, and new product development in its core neurovascular stroke market, as well as peripheral vascular and interventional oncology-related markets.

Scientia's process involves etching slots into a solid nickel-titanium alloy tube to form a closed loop and interconnected beams—allowing the guidewire to effectively transmit torque while meandering through the brain's small, winding blood vessels. The company states that this method offers advantages not found in traditional braided and coil-reinforced guidewires.

Scientia's Aristotle guidewires are available in various sizes. In addition, Scientia also sells Socrates aspiration catheters and Plato microcatheters, the latter designed for delivering embolic coils and stents, as well as liquid embolic agents—such as Medtronic's Onyx platform, which received new FDA approval late last year for the surgical treatment of subcutaneous hematomas.

The transaction is expected to close in the first half of Medtronic's fiscal year 2027 (i.e., from late April to the end of October this year). Regarding the acquisition, Medtronic stated that Scientia's product catalog can be seamlessly integrated into the company's existing interventional product line, such as stent thrombectomies. Furthermore, this acquisition gives Medtronic a complete product portfolio, providing a solid foundation for the company and supporting the treatment of hemorrhagic and acute ischemic stroke.

It's worth noting that the neurointerventional field has seen considerable popularity in recent years. Prior to Medtronic's acquisition, Boston Scientific announced in January of this year its massive $14.5 billion acquisition of Penumbra and its vascular devices. This deal will include hardware for treating peripheral, coronary, and pulmonary thrombosis, as well as stroke treatment devices, encompassing catheters of various sizes from microcatheters to large-diameter catheters, and aspiration and reperfusion systems.

https://news.yaozh.com/archive/47458.html